1 completed, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow BTH1677: new trials by email Literature Review of BTH1677 trials Research Report on BTH1677
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma odetiglucan, CDX-1140 - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | HiberCell, Inc. | 5 | 2022-12-15 | 2024-04-10 |
| Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) Imprime PGG, Pembrolizumab - Malignant Neoplasm of Breast | Phase 2 | Completed | HiberCell, Inc. | 26 | 2021-11-09 | 2023-06-22 |
| Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma Imprime PGG, Pembrolizumab - Pathologic Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Withdrawn | HiberCell, Inc. | 2021-08-15 | 2021-11-05 |
Breast Neoplasms (1) · Melanoma (1)
HiberCell, Inc. (3)
United States (3)
Alison Stopeck, MD (1) · Mark O'Hara (1)